Benaroya Research Institute

Diabetes Clinical Research Program

Diabetes Clinical Research Program
1201 9th Ave
Seattle, WA 98101
United States
Call 800-888-4187 Email this location
Benaroya Research Institute (BRI) is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Carla Greenbaum, MD, the TrialNet team at BRI is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Our Team
Principal Investigators 
Carla
Greenbaum
MD
Director, Diabetes Clinical Research Program, TrialNet Chair
Dr. Greenbaum joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board, which provides oversight for clinical studies. She currently serves as Chair of Type 1 Diabetes TrialNet
Sandra
Lord
MD
Wei
Hao
MD
Dana
VanBuecken
ARNP-BC
Research Coordinators 
Marli
McCulloch-Olson
Mary
Ramey
RD, CDE
Corinna
Tordillos
Jenna
Snavely
Nancy
Wickstrom
David
Kang
"We want to thank every person who has taken part of research over the past 20 years. Because of their participation, we can now identify the disease in earlier stages, long before symptoms appear. The next step is to find a way to stop the disease from progressing and prevent symptomatic type 1 diabetes." Carla Greenbaum, MD

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with BRI to offer convenient participation in our research programs
Bend

Endocrinology Services Northwest
929 SW Simpson Ave, Ste 220, Bend, OR 97702

Billings

St. Vincent Healthcare Diabetes Center
2900 12th Ave North, STE 10 West, Billings, MT 59101

Billings

Billings Clinic Diabetes Center
801 N 29th St, Billings, MT 59101

Boise

St. Lukes Humphreys Diabetes Center
701 E. Morrison Knudsen Dr, Suite 100, Boise, ID 83712

Idaho Falls

Rocky Mountain Diabetes and Osteoporosis Center, PA
3910 Washington Parkway, Idaho Falls, ID 83404

Portland

Oregon Health Sciences University
3181 SW Sam Jackson Park Rd, OP05-DC, Portland, OR 97239

Portland

Legacy Emanuel Childrens Hospital
501 N. Graham St Ste 375, Portland, OR 97227

Richland

Kadlec Medical Center Diabetes Learning Center
888 Swift Blvd, Richland, WA 99352

Seattle

Childrens Hospital & Regional Medical Center
1900 Ninth Ave, M/S JMB-9C, Seattle, WA 98101

Spokane

Sacred Heart Medical Center
105 W. 8th Ave., Spokane, WA 99204

Research Studies

The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information.
Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.

More

Prevention Study

Abatacept

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.

More

Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.

More

Longterm

Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.

More